ACP-105
Muscle & Strength · SARM
Tier D
Bottom line
Read Off Label grades ACP-105 as D (3.3/10) based on very weak evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Obscure SARM with minimal human exposure.
Studied, labeled, or reported-use context: Typical illicit: 5-15 mg/day PO — NOT FDA-approved; gray market; banned sport; not individualized guidance.
Citation correction in progress
1 PubMed link was found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Obscure SARM with minimal human exposure. Acadia stopped development years ago. Sold by research chemical vendors with standard SARM pitch despite absence of efficacy or safety data in humans.
Mechanism
Non-steroidal partial AR agonist; developed by Acadia Pharmaceuticals originally for cognitive indications in hypogonadism; tissue-selective profile claimed
Studied, labeled, or reported dose & route
Typical illicit: 5-15 mg/day PO
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about ACP-105's effects?
- Read Off Label rates the evidence for ACP-105 as Very Weak and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Obscure SARM with minimal human exposure.
- What safety findings are reported for ACP-105?
- ACP-105 has a unclear risk profile in the database. Unknown Legal status: NOT FDA-approved; gray market; banned sport.
- What doses or routes are reported for ACP-105?
- Typical illicit: 5-15 mg/day PO This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does ACP-105 work?
- Non-steroidal partial AR agonist; developed by Acadia Pharmaceuticals originally for cognitive indications in hypogonadism; tissue-selective profile claimed
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.